Skip to content

Business Development

Evox has created a comprehensive intellectual property estate dominating the exosome therapeutics landscape. Our proprietary DeliverEXTM platform enables loading of exosomes with diverse drug cargos, leverages the unique tissue targeting properties of exosomes, and supports proprietary manufacturing and purification methods for advanced exosome therapeutics.

Through partnering with leading organisations, we seek to maximise the potential of exosome therapeutics, either by solving delivery and development challenges for partners using our proprietary DeliverEXTM platform or to accelerate the development of our in-house rare disease assets with the aid of outside expertise and capabilities.

Partnering discussions fall into two areas:

Platform partnering opportunities 

Evox seeks partners for our DeliverEXTM platform who have promising drug targets that are difficult to reach with conventional means or have drug candidates or products that could be improved through exosome engineering.

  1. Engineering of exosome therapeutics to enable the delivery of various drug cargoes, for instance, protein biologics, antibodies, AAV, RNA therapeutics (siRNA, ASO, mRNA) or gene editing modalities
  2. Targeted exosome-mediated drug delivery

Pipeline partnering opportunities 

We have a relentless commitment to progressing our rare disease programs to impact patients' lives and we are always on the lookout for partners who can help us achieve this aim.

For business development opportunities, please reach out here.